An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

In the latest results from the 457-patient B-Clear study, published in the New England Journal of Medicine, bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis ...

The biotech is collaborating with pharma giant Gilead Sciences, which will have the right to opt in to further development and commercialization of the drug following the phase 1b study. Late last ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

(Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI- ...

At FDA, full vaccine approval is the gold standard. The agency was on track to sign off on Novavax’s license by its April 1 ...

Protein-based vaccines have been used for years to prevent other diseases including hepatitis B and shingles. Each year, the three manufacturers update their vaccine recipes to better match the ...

MAH CET Answer Key 2025 objection window opens today, April 21, 2025. The steps to raise objections is given here. State Common Entrance Test Cell, Maharashtra will open the objection window for ...

US health officials move to phase out artificial dyes from the food ... used for years to prevent other diseases including hepatitis B and shingles. Each year, the three manufacturers update ...

Security support for Microsoft's Windows 10 will end in six months, but there is growing scepticism in New Zealand of the need for such a strict cutoff.On Oct 14, Microsoft will no longer support ...